Little Andrew S, Gardner Paul A, Fernandez-Miranda Juan C, Chicoine Michael R, Barkhoudarian Garni, Prevedello Daniel M, Yuen Kevin C J, Kelly Daniel F
1Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona.
2Department of Neurosurgery, University of Pittsburgh, Pennsylvania.
J Neurosurg. 2019 Nov 15;133(6):1732-1738. doi: 10.3171/2019.8.JNS191012. Print 2020 Dec 1.
Recovery from preexisting hypopituitarism after transsphenoidal surgery for pituitary adenoma is an important outcome to investigate. Furthermore, pituitary function has not been thoroughly evaluated after fully endoscopic surgery, and benchmark outcomes have not been clearly established. Here, the authors characterize pituitary gland outcomes with a focus on gland recovery following endoscopic transsphenoidal removal of clinically nonfunctioning adenomas.
This multicenter prospective study was conducted at 6 US pituitary centers among adult patients with nonfunctioning pituitary macroadenomas who had undergone endoscopic endonasal pituitary surgery. Pituitary gland function was evaluated 6 months after surgery.
The 177 enrolled patients underwent fully endoscopic transsphenoidal surgery; 169 (95.5%) of them were available for follow-up. Ninety-five (56.2%) of the 169 patients had had a preoperative deficiency in at least one hormone axis, and 20/95 (21.1%) experienced recovery in at least one axis at the 6-month follow-up. Patients with adrenal insufficiency were more likely to recover (10/34 [29.4%]) than were those with hypothyroidism (8/72 [11.1%]) or male hypogonadism (5/50 [10.0%]). At the 6-month follow-up, 14/145 (9.7%) patients had developed at least one new deficiency. The study did not identify any predictors of gland recovery (p ≥ 0.20). Permanent diabetes insipidus was observed in 4/166 (2.4%) patients. Predictors of new gland dysfunction included a larger tumor size (p = 0.009) and Knosp grade 3 and 4 (p = 0.051).
Fully endoscopic pituitary surgery resulted in improvement of pituitary gland function in a substantial minority of patients. The deficiency from which patients were most likely to recover was adrenal insufficiency. Overall rates of postoperative permanent diabetes insipidus were low. This study provides multicenter benchmark neuroendocrine clinical outcome data for the endoscopic technique.
垂体腺瘤经蝶窦手术后既往垂体功能减退的恢复情况是一项重要的研究结果。此外,全内镜手术后垂体功能尚未得到充分评估,且尚未明确确立基准结果。在此,作者对垂体结局进行了特征描述,重点关注内镜经蝶窦切除临床无功能腺瘤后的腺体恢复情况。
这项多中心前瞻性研究在美国6个垂体中心对患有无功能垂体大腺瘤且接受了内镜鼻内垂体手术的成年患者进行。术后6个月评估垂体功能。
177例入组患者接受了全内镜经蝶窦手术;其中169例(95.5%)可进行随访。169例患者中有95例(56.2%)术前至少有一个激素轴功能减退,其中20/95例(21.1%)在6个月随访时至少有一个轴功能恢复。肾上腺功能不全的患者比甲状腺功能减退(8/72例[11.1%])或男性性腺功能减退(5/50例[10.0%])的患者更有可能恢复(10/34例[29.4%])。在6个月随访时,14/145例(9.7%)患者出现了至少一种新的功能减退。该研究未发现腺体恢复的任何预测因素(p≥0.20)。4/166例(2.4%)患者出现永久性尿崩症。新的腺体功能障碍的预测因素包括肿瘤体积较大(p = 0.009)和克诺斯普分级3级和4级(p = 0.051)。
全内镜垂体手术仅使少数患者的垂体功能得到改善。患者最有可能恢复的功能减退是肾上腺功能不全。术后永久性尿崩症的总体发生率较低。本研究为内镜技术提供了多中心基准神经内分泌临床结局数据。